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The	idea	of	the	benefit	of	increasing	dose	intensity	
was	based	on	 two	known	hypotheses.	The	 first	one,	
Goldie-Coldman̓s	hypothesis,	postulates	that	spontane-
ous	development	of	drug	resistance	following	exposition	
to	cytotoxic	agents	has	a	measurable	velocity.	The	bigger	
the	tumor	size,	 the	greater	 is	 the	number	of	resistant	
clones.	The	result	 is	 that	early	and	frequent	 intensive	
treatment	may	prevent	the	development	of	resistance	
and	ineffective	of	oncologic	therapy.	
The	 second	 is	 Norton-Simon	 hypothesis	 on	
Gomperzian̓s tumour growth kinetics , presumes that	 	 	 	 	 	 	
a	small	tumor	grows	more	quickly	than	a	large	one.	The	
kinetics	of	tumor	growth	is	non-exponential.	The	more	
the	cancer	cells	are	destroyed	by	chemotherapy,	the	
more	quickly	they	are	renewed	�1–4�.
In	1994,	with	regard	to	the	state	of	knowledge	at	that	
time,	we	started	our	program	of	breast	cancer	treatment	
in	women	at	our	department.	First	by	high-dose	chemo-
therapy	and	later	by	intensive	cyclic	chemotherapy	with	
support	of	autologous	peripheral	haemopoietic	stem	
cell	 transplantation	 (PBPC).	 Intensive	cyclic	chemo-
therapy	and	its	conception	was	based	on	the	presump-
tion	that	only	one	even	highly	effective	chemotherapy	
course	(and	dose)	 is	mostly	not	effective	enough	for	
eradication	of		very	sensitive	tumors	�5–6�.	Therefore,	
it	was	 rightly	supposed	 that	administration	of	more	
courses	of	intensive	cyclic	chemotherapy	could	be	more	
effective	than	the	conventional	dosage	�3�.	
The	strategy	of	intensive	sequential	chemotherapy	
was	designed	on	the	presumption	that	chemotherapy	
with	two	consecutive	regimens	and	with	non-crossed	
resistance	would	bring	much	better	effect.	Bonadonna	
et	al.	�7�	documented	the	benefit	of	sequential	admi-
nistration	in	the	study	with	doxorubicin	and	CMF	applied	
sequentially	and	alternatively	to	405	women	with	breast	
cancer	and	more	than	4	positive	lymph	nodes.	The	cu-
mulative	dosage	of	cytostatic	agents	was	the	same	in	
both	arms,	but	better	result	was	ascribed	to	higher	dose-
intensity	in	the	arm	with	sequential	treatment	�7�.
The	original	motive	of	our	study	was	based	on	the	
results	published	by	Bastholt	et	al.	�8�.	They	investi-
gated	the	efficacy	and	toxicity	of	epirubicin	given	to	
female	patients	with	metastatic	breast	cancer.	The	pre-
sented	outcomes	suggested	a	linear	“dose-response”	
relation	 for	 antracyclin-based	 regimens,	 though	a	
threshold	effect	could	not	be	eliminated �8�.	
Here	we	present	the	results	of	treatment	in	a	group	
of	40	women	observed	for	10	years.	All	patients	received	
6	cycles	of	adjuvant	intensive	cyclic	combined	chemo-
therapy	with	epirubicin	150	mg/m2	and	cyclophospha-
mide	1250	mg/m2	(EC)	applied	every	14	days.	At	the	
beginning	of	 the	 treatment	phase	 there	was	a	great	
problem	with	haematological	 toxicity.	To	overcome	
this	serious	complication	autologous	bone	marrow	
transplantation	and,	 later	on,	autologous	peripheral	
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blood	progenitor	cell	 transplantation	(PBPCs)	or	ad-
ministration	of	whole	blood	enriched	with	PBPC	were	
used.	Haemopoiesis	reparation	after	EC	regimen	with	
PBPC	or	whole	blood	transfusion	was	sufficient,	with	no	
necessity	to	reduce	chemotherapy	dosage	�9�.
The	main	aim	of	our	paper	is	to	contribute	to	ob-
jectification	of	currently	widely	discussed	 results	of	
overall	survival	(OS),	time	from	complete	remission	to	
the	first	signs	of	relapse	—	disease	free	survival	(DFS)	
and	time	from	relapse	to	tumor	progression	(TTP)	in	
women	with	breast	cancer.	According	to	our	results,	
we	 think	 that	we	cannot	clearly	demonstrate	better	
curative	effect	with	 intensive	cyclic	 chemotherapy	
when	compared	with	 the	control	group	 treated	by	
conventional	 chemotherapy.	Our	 study,	 however,	
repeatedly	shows	that	using	both	high-dose	or	cyclic	
intensive	chemotherapy	—	we	must	be	very	careful	in	
interpretation	outcomes,	and	partial	success	does	not	
entitle	us	to	make	premature	conclusions.
patIents and methods
Forty	consecutive	patients	 fulfilling	 the	eligibility	
criteria	were	admitted	 to	 the	study.	The	mean	age	
was	44.8	years	(range	31–56	years).	Fifty–six	women	
were	included	in	the	control	group,	their	average	age	
was	55.4	years	(range	31–77	years)	(Table).	Informed	
consent	was	 obtained	 from	each	 of	 the	 patients	
prior	 to	 treatment.	 Follow	up	was	10	 years	 (range	
108–125	months).
Eligibility criteria for admission to the protocol. 
Patients	with	stage	 II	breast	cancer	with	more	 than	
10	positive	 axillary	 lymph	nodes	and	conservative	
surgery	with	axillary	lymph	node	dissection	were	eli-
gible	for	admission.	These	patients	had	biopsy-proven	
locally	advanced	or	inflammatory	breast	carcinoma,	
stages	 III	 and	 IV	but	no	mastectomy	or	metastatic	
disease	without	CNS	and	BM	involvement.	The	perfor-
mance	status	was	0	or	1	(WHO	scale).	The	patients	had	
no	previous	or	concomitant	malignancy,	no	significant	
cardiac	disease,	normal	blood	count	 (pretreatment	
neutrophils >	2	x	109/l,	platelets	>	100	x	109/l),	and	
normal	basic	biochemical	parameters.	They	had	not	
received	previous	chemotherapy.
Mobilization procedures and chemotherapeutic 
regimen.	All	patients	 received	six	cycles	of	chemo-
therapy	at	14-day	intervals	consisting	of	epirubicin	at	
the	dose	of	150	mg/m2	and	cyclophosphamide	at	the	
dose	of	1250	mg/m2	(EC)	on	day	1.	In	the	first	cycle,	
24	h	after	chemotherapy,	mobilization	was	started	with	
a	s.	c.	application	of	G-CSF	(Roche,	Basel	Switzerland)	
at	the	dose	of	5	μg/kg/day	for	the	next	13	days.	In	all	
remaining	cycles,	G-CSF	was	given	 from	day	7	after	
chemotherapy.	 In	 the	 first	cycle	of	 intensive	chemo-
therapy,	leukaphereses	were	performed	on	days	11,	12	
and	13,	and	whole	blood	collection	was	performed	on	
day	14.	On	day	15	the	second	cycle	of	chemotherapy	
was	applied	and	whole	blood,	taken	the	day	before,	was	
reinfused	(day	2	of	the	second	cycle).	In	the	third	cycle	
whole	blood	was	collected	on	day	13,	chemotherapy	
was	applied	on	day	14,	and	whole	blood	was	reinfused	
on	day	15.	In	the	fourth	to	sixth	cycles,	no	whole	blood	
was	collected,	and	cryopreserved	leukapheresed	PBPC	
for	haematopoietic	rescue	were	used	instead.
PBPC harvest and application.	PBPC	were	col-
lected	by	leukaphereses	during	G-CSF	administration	
in	 the	 first	chemotherapy	cycle.	The	 leukaphereses	
were	performed	using	an	automated	COBE	Spectra	
continuous	blood	flow	cell	separator	(COBE	BCT,	Lake-
wood,	CO)	with	the	following	parameters:	blood	volume	
processed	10,000–12,000	ml	(median	11,000	ml)	per	
procedure	and	inlet	flow	rate	60–70	ml/min.	The	origi-
nal	COBE	MNC	program	was	used,	software	version	
5.1	with	quick	start.	The	inlet/AC	ratio	was	1.12.	PBPC	
were	cryopreserved	with	10%	DMSO	in	a	stabilization	
solution	containing	dextran,	sucrose,	dextrose,	and	an-
ticoagulants.	HSA	was	added	to	a	final	concentration	of	
1%.	The	product	was	frozen	in	a	Kryo-10	programmable	
freezer	(Planner,	Biomed,	UK)	with	a	controlled	rate	of	
freezing	(–1	K/min	to	–90	˚ C,	–5	K/min	to	–150	˚C).	After	
freezing,	PBPC	were	stored	in	liquid	nitrogen	at	–196	˚ C.	
Thawing	was	performed	in	a	waterbath	at	37	˚C,	and	the	
suspension	was	infused	into	a	central	venous	catheter	
directly	from	the	freezing	bags	(Baxter	Fenwal,	Deer-
field,	IL)	without removal of the cryoprotectant.	 	 	 	
Whole blood collection.	In	the	first	and	second	
cycles,	whole	blood	was	collected	on	the	last	day	of	
each	cycle	into	standard	blood	collection	bags	(Japan	
Medical	Supply	�JMS�	(S) PTE,	Ltd.,	Singapore)	con-
taining	50	ml	of	CPDA	solution	as	an	anticoagulant.	
The	total	volume	of	whole	blood	was	450	ml.	The	bags	
were	stored	in	a	refrigerator	at	the	tissue	bank	at	4	°C	
for	2	days	before	being	reinfused	after	chemotherapy	
in	the	next	cycle.	
Flow cytometry and colony assays.	Mono-
nuclear	cells	 (MNC)	expressing	 the	CD34	surface	
membrane	antigen	were	quantified	by	flow	cytometry	
using	the	Con	IgG	I-FITC	antibody	and	the	CD34	FITC-
conjugated	8G12	antibody	 (HPCA-2	FITC)	 (Becton	
Dickinson,	Mountain	 View,	CA).	Cytofluorometric	
analysis	was	performed	using	a	FACScan	 (Becton	
Dickinson)	after	lysis	of	the	erythrocytes	with	ammo-
nium	chloride-EDTA.	The	minimum	number for each	 	 	
test	was	10,000,	and	 the	count	of	CD34+	cells	was	
performed	in	a	wide	gate.	However,	it	was	possible	to	
exclude	the	debris	and	the	erythrocytes	by	using	the	
forward	scatter	characteristics	CD45	 fluorescence	
dot	plot.	Haematopoietic	progenitor	cells	(HPCs)	were	
determined	by	CFU-GEMM,	BFU-E,	and	CFU-GM.	
Isolated	purified	MNC	were	plated	at	a	concentration	
of	2	x	105/ml.	All	semisolid	cultures	were	performed	in	
duplicate	and	stimulated	with	50	ng/ml	GM-CSF,	IL-3	
and	3	IU/ml	EPO.	CFU,	GM,	CFU-GEMM,	and	BFU-E	
colonies	were	counted	after	14	days	of	incubation	in	
5%	CO2,	and	5%	O2,	at	37	°C.	The	medium	consisted	of	
IMDM	supplemented	with	10%	BSA,	20%	FBS,	100	μg 
3%	glutamine,	100	μg	penicillin	+	streptomycin,	135	μg	
7.5%	NaHCO3,	and	0.9%	methylcellulose.	Aliquot	volu-
mes	of	1	ml	were	plated	in	duplicate	in	35	mm	Petri	
dishes.	Only	aggregates	with	more	than	40	cells	were	
considered	colonies	and	were	scored	using	an	inverted	
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Olympus	OSP-2	microscope	after	14	days	of	CFU-GM	
or	after	18	days	of	BFU-E	and	CFU-GEMM	incubation	
at	37	°C	in	a	5%	CO2,	fully	humidified	atmosphere.
Statistical analysis. The	main	 end	points	 for	
the	comparison	of	 the	 three	 treatments	were	overall	
survival,	disease-free	survival	and	time	to	tumor	pro-
gression.	Overall	 survival	 (OS)	was	calculated	 from	
diagnosis	determination	to	death	from	any	cause.	Data	
on	patients	known	to	be	alive	at	the	time	of	the	analysis	
were	censored	at	the	time	of	their	last	follow-up	visit.	
Disease-free	survival	(DFS)	was	calculated	from	diag-
nosis	determination	to	relapse	from	any	cause.	Data	on	
patients	known	to	be	alive	and	without	a	relapse	at	the	
time	of	analysis	were	censored	at	the	time	of	their	last	
follow-up	visit.	Time	to	 tumor	progression	(TTP)	was	
calculated	from	relapse	determination	to	time	of	tumor	
progression	from	any	cause.	Data	on	patients	known	to	
be	alive	at	the	time	of	an	analysis	were	censored	at	the	
time	of	their	last	follow-up	visit.	All	treatment	compari-
sons	are	based	on	the	intention-to-treat	principle.	The	
Kaplan-Meier	method	was	used	to	estimate	curves	for	
OS,	DFS	and	TTP,	and	comparisons	were	made	with	
the	use	of	the	log-rank	test.	Cox	proportional-hazards	
models	were	fitted	 in	order	 to	estimate	hazard	ratios	
and	confidence	 intervals.	Differences	 in	 the	overall	
treatment	comparison	and	the	treatment	comparison	of	
the	control	group	were	with	95%	confidence	intervals.	
All	p	values	are	based	on	two-side	tests.
results
Mobilization procedure — mean yields of col-
lected PBPC and whole blood.	In	all	40	treated	pa-
tients,	the	mean	WBC	count	before	EC	and	G-CSF	ad-
ministration	was	6.40	x	109/l	(range	2.30–12.10	x	109/l).	
They	decreased	by	day	8	to	1.20	x	109/l	(range	0.60–
2.70	 x	 109/l)	 and	 increased	again	 to	 12.60	x	 109/l	
(range	1.10–42.60	x	109/l)	by	day	10.	The	peak	value	
of	WBC	50.10	x	109/l	(range	21.10–88.00	x	109/l)	ap-
peared	by	day	14.	The	mean	number	of	CD34+	cells	
in	peripheral	blood	before	chemotherapy	was	3.70	x	
107/l	(range1.30–9.20	x	107/l).	The	first	peak	was	ob-
served	on	day	4	(mean	9.10	x	107/l,	range	0.20–17.40	x	
107/l),	a	decrease	with	minimal	values	was	seen	on	
day	8	(mean	1.39	x	107/l,	range	0.20–2.90	x	107/l),	and	
the	second	peak	appeared	on	day	14	(mean	64.40	x	
107/l,	range	31.20–134.40	x	107/l).	The	mean	number	
of	 circulating	progenitors	 (CFU-GM)	 in	peripheral	
blood	before	chemotherapy	was	2.10	x	105/l	 (range	
0.90–5.30	x	105/l).	After	cytostatics	and	G-CSF,	 the	
numbers	increased	with	the	first	peak	by	day	4	(mean	
15.7	x	105/l,	 range	0.7–70.0	x	105/l)	and	decreased	
to	minimal	values	by	day	8	(mean	1.82	x	105/l,	range	
0–4.30	x	105/l),	and	the	second	peak	was	observed	
by	day	14	(mean	179.10	x	105/l,	range	19.10–383.30	x	
105/l).	The	mean	number	of	circulating	progenitors	
(BFU-E)	in	peripheral	blood	before	chemotherapy	was	
4.20	x	105/l,	range	2.20–9.80	x	105/l).	After	cytostatics	
and	G-CSF,	their	numbers	increased	with	the	first	peak	
by	day	4	(mean	29.7	x	105/l,	range	3.70–139.0	x	105/l)	
and	decreased	to	minimal	values	by	day	8	(mean	2.32	x	
105/l,	 range	1.12–8.20x105/l),	and	 the	second	peak	
was	observed	by	day	14	(mean	402.7	x	105/l,	range	
59.60–813.40	x	105/l).	The	mean	number	of	circulating	
progenitors	(CFU-GEMM)	in	peripheral	blood	before	
chemotherapy	was	0.50	x	105/l	(range	0–1.40	x	105/l).	
After	cytostatics	and	G-CSF,	their	numbers	increased	
with	the	first	peak	by	day	4	(mean	2.7	x	105/l,	range	
0.7–9.0	x	105/l)	and	decreased	to	minimal	values	by	
day	8	(mean	0.22	x	105/l,	range	0–1.20	x	105/l),	and	the	
second	peak	was	observed	by	day	14	(mean	22.10	x	
105/l,	range	1.60–51.30	x	105/l).	Absolute	peak	levels	
of	circulating	CFU-GM,	BFU-E,	CFU-GEMM,	CD34+	
cells	and	 leukocytes	 in	peripheral	blood	were	seen	
approximately	on	day	14.	PBPC	harvesting	was	started	
as	soon	as	there	was	evidence	of	a	considerable	in-
crease	in	WBC	count	after	the	chemotherapy-induced	
nadir.	This	usually	occurred	10	days	after	application	
of	cytostatics.	Altogether	 three	 leukaphereses	were	
performed,	and	the	maximum	harvest	was	achieved	on	
day	13.Onday14 (peak incidenceofCFU-GM,BFU-E,	 	 	 	 	 	 	 	 	
and	CFU-GEMM),	the	median	increment	of	absolute	
values	of	CFU-GM	over	 the	baseline	was	approxi-
mately	853-fold,	BFU-E	was	959-fold,	CFU-GEMM	
was	44.2-fold,	and	CD34+	cells	was	17.4-fold.
Application of progenitors and haematopoietic 
recovery. The	mean	values	of	applied	progenitors	per	
cycle	were	CD34+	cells	1.52	x	106/kg,	CFU-GM	1.18	x	
105/kg,	BFU-E	2.54	x	105/kg,	and	CFU-GEMM	0.31	x	
105/kg	in	the	courses	supported	by	whole	blood	and	
CD34+	2.04	x	106/kg,	CFU-GM	1.59	x	105/kg,	BFU-E	
2.87	x	105/kg,	and	CFU-GEMM	0.34	x	105/kg	 in	 the	
leukapheresis-supported	courses.	The	applied	dose	of	
cytostatics	and	intervals	were	identical	in	all	patients.	
Leukopenia	 in	patients	supported	with	whole	blood	
(second	and	 third	cycles)	 vs	 leukapheresed	PBPC	
(fourth	through	to	sixth	cycles)	was	as	follows:	grade	4,	
13/6	(38.2%/17.6%),	grade	3,	19/23	(55.9%/70.6%),	
and	grade	2,	1/4	(2.9%/11.8%),	respectively.	Throm-
bocytopenia	was	grade	4,	11/6	(32.4%/17.6%),	grade	
3,	10/7	(29.4%/20.6%),	grade	2,	7/13	(20.6%/38.2%),	
and	grade	1,	6/6	(17.6%/17.6%),	respectively.	 In	all	
patients,	 the	mean	number	of	platelet	 transfusions	
applied	either	as	whole	blood	or	leukapheresed	PBPC	
was	3	vs	2	(range	2–6	vs	0–4)	per	cycle.	The	mean	
number	of	erythrocyte	transfusions	was	7	vs	2	(range	
4–8	vs	1–4)	per	cycle.	The	difference	in	the	number	
was	not	significant	at	p	<	0.001,	whereas	in	erythrocyte	
transfusions,	the	difference	at	p	<	0.001	was	statisti-
cally	 significant	because	Hb	 levels	did	not	exceed	
105	g/l,	which	was	why	 the	number	of	erythrocyte	
transfusions		increased.	
Evaluation of clinical results. We	performed	a	
follow-up	analysis	of	all	patients.	The	follow-up	period	
was	10	years	(range	108–126	months).	In	the	group	with	
intensive	cyclic	chemotherapy	(EC)	responses	in	high-
risk	patients	previously	treated	with	surgery	and	then	
with	adjuvant	chemotherapy	(n	=	5)	were	not	evaluated.	
The	response	rate	(RR)	in	patients	with	locally	advanced	
or	inflammatory	breast	carcinoma	(n	=	10)	was	80%,	
CR	was	80%,	and	PR	was	10%.	No	response	to	therapy	
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was	observed	in	10%.	In	women	with	metastatic	disease	
(n	=	17),	RR	was	76.4%,	CR	was	not	achieved,	and	
PR	was	58.8%.	Two	patients	died	during	the	therapy.	
The	control	group	consisted	of	56	women	with	breast	
cancer	and	adjuvant	FAC	chemotherapy	—	fluorouracil,	
doxorubicin,	cyclophosphamide,	in	6	cycles	(85,7%) .	 	
CMF	—	cyclophosphamide,	methotrexate,	fluorouracil	
(10.7%)	—	6	cycles	in	66,7%	and	weekly	doxorubicin	
(3.6%)	—	10	cycles	given	to	all	patients.	The control	 	
group	was	made	up	of	56	women	with	breast	cancer,	
85.7%	of	whom	received	6	cycles	of	FAC	chemotherapy	
(fluorouracil,	doxorubicin,	cyclophosphamide),	10.7%	
received	CMF	 (cyclophosphamide,	methotrexate,	
fluorouracil;	6	cycles	in	66.7%	of	this	group),	and	3.6%	
received	10	cycles	of	weekly	doxorubicin	 in	adjuvant	
setting.	The	response	rate	(RR)	in	patients	with	locally	
advanced	or	inflammatory	breast	carcinoma	(n	=	26)	
was	88.5%,	CR	was	80.7%,	and	PR	was	19.3%.	No	re-
sponse	to	therapy	was	observed	in	3	patients.	In	women	
with	metastatic	disease	(n	=	19),	RR	was	52.6%,	CR	was	
not achieved, and PR was 47.3%. Evaluation of RR re-	 	 	 	 	 	 	 	 	
sults	in	the	group	with	intensive	cyclic	EC	chemotherapy	
and	 in	 the	control	group	showed	 that	 the	difference	
of	80%	vs	88.5%	(p	=	0.870)	in	the	group	with	locally	
advanced	or	inflammatory	breast	carcinoma		was	not	
statistically	significant. CR of 80% vs 80.7% was not		 	 	 	 	 	 	 	
statistically	significant.	PR	of	10%	vs	19.3%	(p	=	0.514)	
was	on	the	border	of	significance	for	the	control	group.	
The	difference	in	RR	in	women	with	metastatic	disease	
was	77.4%	vs	52.6%	(p	=	0.326).	This	difference	was	
statistically	significant.	CR	was	not	achieved	 in	any	
group	with	metastatic	carcinoma.	PR	was	58.8%	vs	
47.3%	(p	=	0.427).	This	difference	was	on	the	border	of	
statistical	significance.	Furthermore,we found thatOS,	 	 	 	 	
regardless	of	the	stage	of	the	disease,	was	significantly	
different	(p	=	0.0186)	for	the	benefit	of	women	treated	
by	intensive	cyclic	EC	chemotherapy	with	haemopoi-
etic	support	 (PBPC	or	whole	blood)	 in	comparison	
with	 the	control	group. Evaluation of survival shows	 	 	 	 	
that	the	maximum	difference	in	OS	is	in	the	period	of	
5–7	years	(range	2.8–8.6	years)	and	after	that	time	the	
differences	are	not	so	significant	(Fig.	1,	a).	However,	
when	we	divided	the	patients	into	groups	according	to	
the	stage	of	the	disease and compared them with the	 	 	 	 	 	
identical	control	groups,	we	 found	that	 there	was	no	
statistical	difference	(p	=	0.996)	in	women	with	stage	
II,	the	difference	was	very	small	(p	=	0.035)	in	the	group	
with	stage	III	and	similar	it	was	in		the	group	with	stage	
IV	(p	=	0.0352 (Fig. 1,	 	 	b,	c,	d).	Here, it is not clearwhich	 	 	 	 	 	
group	more	or	less	contributed	to	this	seemingly	good	
result	of	OS (Fig. 1,	 	 	b,	c,	d).	Probably, an important	 	 	
role	played	the	fact	that	maximum	good	results	in	OS	
were	achieved		between	the	years	5	and	7	of	follow-up.	
(Fig.	2,	a).	Evaluation of DFS showed no statistically	 	 	 	 	 	
significant	difference	in	survival	(p	=	0.6703)	between	
the	controls	and	the	patients	regardless	of	the	stage	
of	the	disease		(Fig.	2,	a)	When DFS was compared in	 	 	 	 	
patients	with	stage	II,		this	difference	was	also	not	signifi-
cant	(p	=	0.7909)	and	similar	result	was	found	in	stage	
III	(p	=	0.8579)	and	stage	IV	(p	=	0.6581) (Fig. 2,	 	 	b,	c,	
d).	�et, a very interesting outcomewas noted when we	 	 	 	 	 	 	 	 	
compared	TTP. When TTP was compared in all treated	 	 	 	 	 	 	 	
patients	without	relation	to	the	stage	of	the	disease,	it	
was	statistically	significantly		longer	(p	<	0.001)	than	in	
the	control	group	(Fig. 3,	 	a).	Accordingly it was seen at	 	 	 	 	
TTP	evaluation	in	patients	with	stage	II	and	III (	 p	<	0.001)	
(Fig.	3,	b,	c).	This statistical difference was somewhat	 	 	 	 	
smaller	in	stage IV (	 	 p	=	0.0265)	(Fig.	3,	d).	In	the	relapse	
IV
fig. 1. Kaplan	—	Meier	survival	curves
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period	in	the	2nd	and	3rd	line	47.5%	of	women	received	
combined	chemotherapy	with	paclitaxel/docetaxel	at	
the	beginning	of	therapy	and	combination	of	chemo-
therapy	and	immunotherapy	(paclitaxel/docetaxel	and	
transtuzumab)	was	applied	to	10%	of	women	that	were	
first	treated	with	intensive	EC	chemotherapy.	This was	 	
in	contrast	with	 the	control	group	where	only	5.4%	
of	patients	were	treated	by	a	combination	of	chemo-
therapy	and	 immunotherapy. In addition, hormonal	 	 	 	 	
treatment	was	changed	in	all	patients	with	hormone-
dependent	carcinomas	after	recurrence	of	the	disease.	
The	changes	were	as	follows:	EC	group	—	anastrozol	
42.5%,	letrozol	15%,	control	group	—	anastrozol	12.5%,	
letrozol	5.4%. 95%	of	patients	from	the	group	with	prior	
intensive	chemotherapy	and	only	19.6%	of	patients	from	
the	control	group	were	given	tamoxifen.	
fig. 2. Kaplan	—	Meier	survival	curves fig. 3. Kaplan	—	Meier	survival	curves
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Table. Patients t�eated with intensive cyc��ic chemothe�a�y and cont�o�� g�ou�
Cont�o�� ICCH
Numbe� of �atients 56 4�
Mean age (yea�s) 55�4 
(�ange 
31–��)
44�8 
(�ange 
31–56)
ER+/PR+ 11 9
Stage II b�east cance� (≥ 1� �ositive axi����a�y ��ym�h nodes) 11 13
Stage III and IV b�east cance� (��oca����y advanced b�east 
ca�cinoma )
�6 1�
Metastatic b�east ca�cinoma 19 1�
Notes:� ICCH — intensive cyc��ic chemothe�a�y — e�i�ubicin ���us cyc��o�hos-
�hamide; ER+/PR+ — �atients with est�ogen-�ositive �ece�to� and ��oges-
te�one-�ositive �ece�to�; Stage II�� III and IV — �me�ican Joint Committee 
on Cance� Staging�
dIsCussIon
The	idea	about	benefit	from	increasing	dose	intensity	
is	based	on	 two	known	hypotheses,	namely,	Goldie-
Coldman̓s	hypothesis	and	Norton-Simon̓s	hypothesis	
�1–2�.Anumberof studieswerethenconductedtoverify	 	 	 		 	 	 	 	 	 	
these	presumptions,	the	aim	being	to	demonstrate	the	
influence	of	high-dose	chemotherapy	on	tumour	treat-
ment. Here we wish to remind some important studies	 	 	 	 	 	 	 	 	
which	in	different	ways	also	influenced	our	approach	and	
further	decision-making	 just	before	starting	the	treat-
ment	of	women	with	breast	cancer	�6�.
One	hundred	and	two	women	with	primary	breast	
cancer	and	more	than	10	positive	axillary	lymph	nodes	
were	admitted	to	the	pilot	study	of	Peters	and	his	group.	
All	patients	were	treated	with	high	doses	of	cyclophos-
phamide,	cis-platin	and	carmustin	with	autologous	bone	
marrow	support �10�. In this study, DFS after 2.5 years	 	 	 	 	 	 	 	 	
was	72%,	which	shows	a	survival	benefit	in	comparison	
with	patients	having	conventional	chemotherapy	�10�.	
This	study	represented	a	certain	stimulus	because,	at	
that	 time,	 the	number	of	patients	with	solid	 tumours	
treated	with	high-dose	chemotherapy	notably increased	 	
.	Theprimary ideaof our studywasbasedon this paper,	 	 	 	 	 	 	 	 	 	 	
but	also	on	the	results	published	by	Bastholt	and	col-
leagues	as	 they	 investigated	the	efficacy	and	toxicity	
of	epirubicin	at	the	doses	of	40,	60,	90	and	135	mg/m2	
applied	to	women	with	metastatic	breast	cancer	every	
3	weeks. They observed an increase in the number of	 	 	 	 	 	 	 	 	
responses	and	prolongation	of	TTP	with	raising	dos-
age	of	epirubicin	from	40	mg/m2	to	90	mg/m2,	but	not	
at	higher	doses. This study concluded that the dosage	 	 	 	 	 	 	
of	90	mg/m2	is	the	optimal	tri-weekly	dose	because	it	
was	not	confirmed	that	doses	higher	 than	90	mg/m2	
improve	outcomes	in	any	way	�8�. This was also one of	 	 	 	 	 	
the	reasons	why	we	chose	intensive	cyclic	combined	EC	
chemotherapy	with	haemopoietic	support	�11�.Over the	 	 	
next	few	years		many	other	studies	were	performed	which	
verified	the	relation	between	dose	and	dose	intensity.	
For	example,	here	we	can	mention	the	Cancer	and	
Leukemia	Group	B	(CALGB)	study	 in	which	1572	pa-
tients	were	analysed. The authors conclude that the	 	 	 	 	 	
effect	may	depend	on	the	dose,	or	that	there	may	be	a	
threshold	dose	below	which	the	clinical	effect	is	signifi-
cantly	worse.BothDFSandOSshowedanupwardtrend	 	 	 	 	 	 	 	 	
to	improve	with	higher	dose	intensity,	but	the	difference	
between	groups	was	not	statistically	significant	 �12�.	
In	1997	Bearman	et	al.	published	their	experience	with	
high-dose	chemotherapy	and	stem	cell	support	as	an	
adjuvant	therapy	for	54	women	with	4–9	positive	axillary	
nodes. Even though the result of DFS evaluation was	 	 	 	 	 	 	 	 	
promising,	the	authors	themselves	admit	that	a	longer	
follow-up	is	necessary	to	compare	survival	time	in	these	
patients	with	historical	controls	 treated	by	standard-
dose	chemotherapy	�13�.Gianni et al. published5-year	 	 	 	 	 	
follow-up	results	of	their	sequential	high-dose	chemo-
therapy	programme	with	stem	cell	support	applied	as	
adjuvant		therapy	in	women	having	breast	cancer	stage	
II	or	III	with	≥10	positive	lymph	nodes.DFSandOSwere	 	 	 	 	
analysed	on	an	intent-to-treat	basis. The difference in	 	 	 	
DFS	was	statistically	significant	between	groups	(p	=	
0.04)	but	not	in	OS.	The	difference	was	on	the	border	of	
statistical	significance (	 p	=	0.05).	The main difference	 	 	
in	treatment	was	probably	radiotherapy	of	the	breast	
or	chest	wall	in	patients	with	high-dose	chemotherapy,	
which	may	be,	at	least	in	part,	the	cause	of	some	differ-
ences	found	between	the	treated	groups	�14�.	
After	a	period	of	 time	when	some	studies	showed	
both	—	good	and	worse	therapeutic	results,	it	was	neces-
sary	to	analyse	the	achieved	results	responsibly.Gener-	
ally,	it	was	accepted	that	more	accurate	results	can	be	
achieved	only	in	large	randomized	studies	�15�. In 1998	 	 	
the	NCI	(National	Cancer	Institute)	gave	priority	to	four	
randomized	trials	with	HDC	and	stem	cell	support	�15�.
We	found	out	that	in	evaluation	of	our	results	we	had	to	
include	other	factors	which	could	influence	the	gathered	
data. There were several such factors in our group of	 	 	 	 	 	 	 	 	 	
40	women	treated	by	intensive	cyclic	EC	chemotherapy.	
It	was	 the	 fact	 that	 the	majority	of	patients	 received	
hormonal	 therapy	with	 tamoxifen	—	95%	vs	19.6%	in	
the	control	group. In addition, hormonal treatment was	 	 	 	 	 	
changed	in	all	patients	with	hormone-dependent	tumours	
after	recurrence:ECgroup—anastrozol42.5%, letrozol	 	 	 	 	 	 	
15%,	controlgroup—anastrozol12.5%, letrozol5.4%of	 	 	 	 	 	 	 	
patients.Furthermore,allwomenthat received intensive	 	 	 	 	 	 	
cyclic	chemotherapy	underwent	breast	 radiotherapy	
as	opposed	to	85.7%	of	women	in	the	control	group.	
But	what	we really think is that our results significantly	 	 	 	 	 	 	 	
influenced	administration	of	paclitaxel/docetaxel	chemo-
therapy	in	47.5%	of	patients	in	2nd	and	3rd	line	following	
cancer	 relapse	as	well	as	 the	 results	with	combined	
chemotherapy	and	immunotherapy	(paclitaxel/docetaxel	
and	transtuzumab)	given	to	10%	of	 the	patients	after	
breast	cancer	recurrence	and	who	were	first	treated	by	
intensive	cyclic	EC	chemotherapy. In contrast to this,	 	 	 	 	
only	5.4%	of	the	patients	in	the	control	group	were	given	
combined	chemotherapy	and	immunotherapy.	
In	1995 Bonadonna et al. published the results of	 	 	 	 	 	 	 	
their	 study,	which	showed	good	 therapeutic	 results	
of	high-dose	chemotherapy	in	women	with	advanced	
breast	cancer. This treatmentwas associatedwith bet-	 	 	 	 	 	
ter	survival	 in	DFS	and	OS	evaluation	 in	comparison	
with	standard	chemotherapy	and	shortened	intervals	
between	cycles.Patientswithhigh-dosechemotherapy	 	 	 	 	
had	better	a	4-year	survival	rate	according	to	evaluation	
of	DFS	than	those	who	received	conventional	chemo-
therapy	(60%	vs	44%). Moreover, the group with high-	 	 	 	 	
dose	chemotherapy	also	showed	better	OS	(75%	vs	
70%) �7�. However, here we also have to remind that	 	 	 	 	 	 	 	 	 	
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these	and	other	results	need	to	be	assessed	with	cau-
tion	because	no	group	received	taxans.	We	think	that	
conclusions	in	this	study	might	have	been	influenced,	
just	as	it	was	in	our	study. This was confirmed by our	 	 	 	 	 	
TTP	result	showing	a	clinically	significant	effect	with	
application	of	 taxans	alone	or	 taxans	 in	combination	
with	immunotherapy.Todayweknowthat increasing the	 	 	 	 	 	 	
dose	with	prophylaxis	of	growth	factors	has	no	benefit	
in	adjuvant	treatment	of	breast	cancer.	It	is	clear now,	 	
that	prospective	clinical	 trials	with	high-risk	patients	
and	high-dose	chemotherapy	with	bone	marrow	or	pe-
ripheral	stem	cell	transplantations	did	not	demonstrate	
statistically	significant	benefit.	In	the	clinical	trial	CALGB	
9082	(Cancer	and	Leukemia	Group	B)	785	women	with	
more	than	10	positive	lymph	nodes	were	evaluated	and	
neither	OS	nor	DFS	were	better	 in	 the	 transplanted	
group	�16�. A Rodenhuis�� study Included 855 patients	 	 	 	 	 	 	
with	more	than	3	lymph	positive	nodes	who	received	5	
cycles	of	FEC	chemotherapy	or	4	standard	cycles	of	
FEC	chemotherapy	plus	one	dose-density	regimen	with	
transplantation.	Though	a	short	improvement	in	5-year	
DFS	(59%	vs	65%)	was	noted,	it	was	without	statistical	
significance.	Only	subanalyses	demonstrated	a	slight	
benefit	in	younger	patients	with	more	than	10	positive	
nodes,	HER-2	negative	and	lower	grade	of	the	disease	
�17�.	Even	more	precise	analysis	did	not	indicate	nega-
tive	 factors	such	as	hormonal	 independence,	HER-2	
negativity,	lower	grade	etc.,	influencing	the	benefit	of	
intensive	cyclic	EC	chemotherapy.	
Presently, results of some current trials show	 	 	 	 	 	 	
that	administration	of	high-dose	chemotherapy	may	
have	a	specific	 importance	 in	 treatment	of	primary	
advanced	—	 inflammatory	 �18,	19�	and	metastatic	
breast	 cancer. For example, in 2006 Vredenburgh	 	 	 	 	 	
et	al.	published	a	study	in	which	they	assessed	OS	in	
425	women	with	metastatic	breast	cancer	after	high-
dose	chemotherapy	with	haemopoietic	support. The	 	
patients	 received	2–4	cycles	of	 inductive	combined	
chemotherapy	with	doxorubicin,	5-fluorouracil	 and	
methotrexat	 (AFM). Women in complete remission	 	 	 	 	
were	randomized	into	the	group	with	high-dose	com-
bined	chemotherapy	 (cyclophosphamide,	cisplatin	
and	carmustine)	plus	haemopoietic	support. The fol-	 	
low-up	period	was	5	years.	Comparison ofOSwomen	 	 	 	
after	 inductive	 chemotherapy	 and	after	HDC	was	
3.8	vs	9.7	months	with	benefit	 for	HDC	(p	<	0.006).	
The	authors	here	prove	that	salvage	HDC	may	prolong	
survival	in	cases	of	metastatic	breast	cancer	�20�.
This	and	other	results	could	be	a	good	reason	to	
conduct	another	clinical	 trials.	However,	 the	present	
results	do	not	justify	the	use	of	high-dose	chemotherapy	
within	the	framework	of	standard	adjuvant	therapy	as	it	
is	still	a	curative	regimen	for	clinical	trials	�21–23�.
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ИНТЕНСИВНАЯ ЦИКЛИЧЕСКАЯ ХИМИОТЕРАПИЯ 
И ТРАНСПЛАНТАЦИЯ АУТОЛОГИЧНыХ КЛЕТОК-
ПРЕДШЕСТВЕННИКОВ ПЕРИФЕРИЧЕСКОЙ КРОВИ 
ИЛИ ЦЕЛЬНОЙ КРОВИ БОЛЬНыМ РАКОМ МОЛОЧНОЙ 
ЖЕЛЕЗы — ДЕСЯТИЛЕТНИЙ МОНИТОРИНГ 
Цель: объективизация широко обсуждаемых результатов по общей выживаемости (O�), периода ремиссии (��) и про-     
должительности периода от рецидива к опухолевой прогрессии (��О�) у больных раком молочной железы. Методы: 
обследовано 40 больных, отвечающих установленным критериям отбора, и 56 здоровых женщин, составивших контроль-
ную группу. У всех больных проведено 6 циклов адъювантной интенсивной циклической комбинированной  химиотерапии 
(эпирубицин — 150 мг/м2 и циклофосфамид — 1250 мг/м2 (ЭЦ)), проводимой каждые 14 дней. Для преодоления гема-
тологической токсичности применяли трансплантацию клеток-предшественников периферической крови (К��К) или 
цельной крови, обогащенной К��К. Результаты: выявлены статистически значимые различия в О�, не зависящие от 
стадии заболевания, у пациенток, получавших интенсивную циклическую химиотерапию ЭЦ, по сравнению с контрольной 
группой. �ри оценке �� не выявлено статистически значимых различий выживаемости между контрольной группой и 
больными во всех стадиях заболевания. ��О� у пациенток независимо от стадии заболевания статистически значимо 
выше, чем таковой контрольной группы. Выводы: по результатам исследования, интенсивная циклическая химиотерапия 
ЭЦ не имеет лечебных преимуществ по сравнению со стандартной дозовой химиотерапией. 
Ключевые слова: интенсивная циклическая химиотерапия, общая выживаемость, период ремиссии, период до опухолевой 
прогрессии, клетки-предшественники периферической крови, цельная кровь, рак молочной железы. 
